Education
About Us
Working with TipRanks
Follow Us
AptarGroup (ATR)
NYSE:ATR
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
1.15Last Year’s EPS
1.2Same Quarter Last Year
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mix of clear operational and commercial strengths—notably strong Q4 revenue growth, sustained Pharma pipeline momentum (including FDA approval of CARDAMYST), meaningful tooling and commercial wins in Beauty and Closures, solid capital returns and a healthy balance sheet—while also disclosing significant near-term margin pressures driven by emergency medicine destocking (~$65 million headwind), operational disruptions in Beauty and Closures, higher interest and tax expenses, and a sizable Q4 EPS decline. Management emphasized that many negative items are transitory, expects sequential margin improvement through 2026 and reaffirmed productivity programs and buyback flexibility. Overall, positive revenue and pipeline momentum are meaningfully offset by near-term margin and cost challenges, leaving a balanced outlook.Company Guidance
Strong Q4 Revenue Growth
Reported sales for Q4 grew 14% year-over-year to $963 million (from $848 million); core sales increased 5%, reflecting healthy underlying demand across the portfolio.
Full Year Revenue and EPS Growth
For FY2025, reported sales increased 5% to $3.8 billion; reported net income rose 5% to $393 million and reported EPS increased 7% to $5.89 (from $5.53).
Pharma Segment Momentum and Pipeline Milestones
Pharma core sales (ex-emergency medicine) grew 10% in Q4; injectables core sales increased 24%. Notable pipeline and commercial milestones include FDA approval of CARDAMYST (Bidose nasal delivery), partnerships on intranasal vaccines, an exclusive ophthalmology agreement with Bausch + Lomb, TGA approval of neffy (needle-free nasal epinephrine), and multiple Phase II studies—underscoring diversification across respiratory, biologics/injectables and systemic nasal delivery.
Adjusted EBITDA and Profitability Base
Q4 adjusted EBITDA of $191 million; adjusted EBITDA margin approximately 19.8%. Full-year adjusted EBITDA increased 5% with full-year adjusted EBITDA margin stable at 21.6%.
Beauty and Closures Top-Line Wins
Beauty core sales grew 10% in Q4 (includes tooling contribution); key product wins include Unilever (Nexxus hair care pump), Chanel (HYDRA BEAUTY Micro Serum custom pump) and Chinese brand launches. Closures saw product volume growth with core sales up 1% (beverage up 7%, food down 1%) and customer wins including McCormick and Coca-Cola in South Africa.
Record Tooling Sales and Customer Retention
Q4 marked a record quarter for tooling sales and FY2025 was the second-highest tooling year in over a decade—positive for customer retention and future revenue opportunities despite tooling's lower margins.
Strong Capital Returns and Buyback Authorization
Returned $486 million to shareholders in 2025 (share repurchases and dividends); repurchased $175 million in Q4 and $365 million total in 2025. Board authorized up to $600 million in new buybacks, replacing prior authorizations.
Healthy Balance Sheet and Cash Generation
Ended year with $410 million cash and short-term investments, net debt ~ $1.1 billion and leverage ratio 1.38. Free cash flow for FY2025 was $303 million (cash from operations $570 million less capital expenditures net of grants $267 million).
Sustainability and Corporate Recognition
Named to CDP Climate A list (top ~4% of companies) and ranked among America's Most Responsible Companies by Newsweek (56 of 600), highlighting leadership in climate action and transparency.
Ongoing Productivity Programs
Management cited sustained structural productivity improvements 'well north of $100 million' (annualized reductions realized from prior initiatives) and ongoing cost-savings efforts, footprint rationalization, automation and centralization to improve scalability and margins.
ATR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ATR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 05, 2026 | $123.98 | $134.31 | +8.33% |
Oct 30, 2025 | $123.88 | $115.56 | -6.71% |
Jul 31, 2025 | $155.96 | $140.28 | -10.05% |
May 01, 2025 | $146.75 | $150.44 | +2.51% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does AptarGroup (ATR) report earnings?
AptarGroup (ATR) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is AptarGroup (ATR) earnings time?
AptarGroup (ATR) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ATR EPS forecast?
ATR EPS forecast for the fiscal quarter 2026 (Q1) is 1.15.